Post-treatment neutrophil-to-lymphocyte ratio (NLR) predicts response to anti-PD-1/PD-L1 antibody in SCLC patients at early phase
Qi Xiong(Chinese PLA General Hospital), Yi Hu(Chinese PLA General Hospital), Bo Yang(Chinese PLA General Hospital), Lingli Xin, Guoqing Zhang(Chinese PLA General Hospital), Jing Zhang(Chinese PLA General Hospital), Ziwei Huang(Nanjing University of Chinese Medicine), Weiwei Shi(Chinese PLA General Hospital), Xiao Zhao(Chinese PLA General Hospital), Boyu Qin(Chinese PLA General Hospital)
Cited by 73
Related Papers
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504
Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias
|Molecular Cancer Therapeutics|2006|186
Structural and Functional Characterization of Human CXCR4 as a Chemokine Receptor and HIV-1 Co-receptor by Mutagenesis and Molecular Modeling Studies
|Journal of Biological Chemistry|2001|138
Bio-template synthesis of Mo-doped polymer carbon nitride for photocatalytic hydrogen evolution
|Applied Catalysis B: Environmental|2019|133
Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis
|Frontiers in Oncology|2021|125